Literature DB >> 17214930

[Construction of a therapeutic effect evaluation system for patients with primary liver cancer based on syndrome differentiation in traditional Chinese medicine].

Dong-tao Li1, Chang-quan Ling, Qing-bo Lang, De-zeng Zhu, Chao-qin Yu, Zhe Chen, Xiao-feng Zhai, Jie Shen, Jin-feng Zhang, Bai-hong Zhang.   

Abstract

OBJECTIVE: To construct a system of therapeutic effect evaluation for patients with primary liver cancer according to the theory of syndrome differentiation in traditional Chinese medicine (TCM), and to examine its reliability.
METHODS: Analytic hierarchy process and 100 mm surveyor's rod method were applied to obtain bottom layer and top level syndromes, which were used to construct the method of therapeutic effect evaluation, and its reliability was verified in clinical practice by comparing with some evaluation criteria in Western medicine, such as cancer severity scale; Karnofsky performance scale; Child-Pugh classification, cancer staging classification, and quality of life scale, etc.
RESULTS: A system of therapeutic effect evaluation was constructed, and it could reflect the progress of tumor, changes of hepatic function and constitution. The evaluation scores acquired from the system were highly associated with the quality of life of the patients.
CONCLUSION: The system of therapeutic effect evaluation can reflect the severity of disease and the characteristics of TCM treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17214930     DOI: 10.3736/jcim20070104

Source DB:  PubMed          Journal:  Zhong Xi Yi Jie He Xue Bao        ISSN: 1672-1977


  1 in total

1.  Therapeutic efficacy of fuzheng-huayu tablet based traditional chinese medicine syndrome differentiation on hepatitis-B-caused cirrhosis: a multicenter double-blind randomized controlled trail.

Authors:  Ya-Nan Song; Ji-Jia Sun; Yi-Yu Lu; Lie-Ming Xu; Yue-Qiu Gao; Wei Zhang; Xiao-Su Wang; Dong-Ying Xue; Qing-Shan Zheng; Shi-Bing Su
Journal:  Evid Based Complement Alternat Med       Date:  2013-03-06       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.